Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638989 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00638989: Completed Phase 1 study, sponsored by MedImmune.
NCT00638989 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00638989, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
Primary Outcome
Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. Absolute bioavailability of the subcutaneous doses was assessed by the geometric least-square means ratios of subcutaneous to intravenous dose-normalized area under the serum concentration-time curve from time zero to infinity (AUC \[0 - infinity\]/Dose). AUC (0 - infinity) = Area under the serum concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time
Interventions
- BIOLOGICAL CAT-354 150 mg (intravenous)
- BIOLOGICAL CAT-354 150 mg (subcutaneous)
- BIOLOGICAL CAT-354 300 mg (subcutaneous)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-04-11 |
| Est. Completion | 2008-06-07 |
| Phase | Phase 1 |
What the finished NCT00638989 record still lists
NCT00638989 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 3 interventions - of which CAT-354 150 mg (intravenous) is the first listed.
NCT00638989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00638989 about?
NCT00638989 is a clinical study titled "A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354". To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
What is the current status of trial NCT00638989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-04-11. Estimated completion is 2008-06-07.
What interventions are being tested in trial NCT00638989?
The interventions under investigation include: CAT-354 150 mg (intravenous) (BIOLOGICAL), CAT-354 150 mg (subcutaneous) (BIOLOGICAL), CAT-354 300 mg (subcutaneous) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00638989?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00638989's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI